Alfred Okeke, MD
Endocrinology, Diabetes & Metabolism · Goldsboro, NCNPI 1093753436
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $180,097 of the $221,549 with a category attached, or 81.3%. Novo Nordisk accounts for 62.5% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $64,963 and has fallen 85.7% since, to $9,281 in 2025. Among endocrinology, diabetes & metabolism clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 408 payments — averaging $543.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$138K
- AstraZeneca$43K
- Bayer$27K
- Mannkind Corporation$5K
- Johnson & Johnson$2K
- Medtronic$2K
- plus $3K from 34 others
What the payments were for
- Consulting fees$1,7001%
- Speaking & faculty fees$180,09781%
- Travel & lodging$29,72713%
- Food & beverage$9,9324%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 155 | $138,406 |
| AstraZeneca(2 entities) | 62 | $43,223 |
| Bayer | 36 | $27,299 |
| Mannkind Corporation | 17 | $5,079 |
| Johnson & Johnson | 9 | $2,382 |
| Medtronic(2 entities) | 18 | $2,065 |
| Sanofi-aventis U.S. LLC | 8 | $465 |
| Lilly USA, LLC | 15 | $266 |
| Zealand Pharma US, Inc. | 3 | $264 |
| Sequel Med Tech, LLC | 2 | $234 |
| Cequr Corporation | 2 | $210 |
| Lundbeck LLC | 11 | $201 |
| Aucta Pharmaceuticals, Inc. | 12 | $166 |
| Corcept Therapeutics | 7 | $138 |
| Neurocrine Biosciences, Inc. | 7 | $123 |
| Neurelis, Inc. | 6 | $116 |
| BETA Bionics, Inc. | 2 | $89 |
| Recordati_rare_diseases_inc. | 4 | $81 |
| Shire North American Group Inc | 1 | $63 |
| Boehringer Ingelheim | 3 | $56 |
| UCB, Inc. | 2 | $55 |
| Radius Health, Inc. | 1 | $50 |
| Merck | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Ascendis Pharma Endocrinology Inc | 2 | $42 |
| Amgen | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Averitas Pharma Inc. | 1 | $32 |
| AbbVie | 2 | $32 |
| GSK | 2 | $30 |
| Verona Pharma, Inc. | 1 | $29 |
| TG Therapeutics, Inc. | 1 | $27 |
| Inogen, Inc. | 1 | $26 |
| Abbott | 1 | $24 |
| Insulet Corporation | 1 | $24 |
| EMD Serono, Inc. | 1 | $23 |
| Grifols USA, LLC | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$69,532
- RYBELSUS$48,474
- FARXIGA$42,271
- Kerendia$26,723
- Tresiba$12,482
- AFREZZA$4,542
- Xultophy 100/3.6$3,900
- INVOKANA$2,340
- MINIMED 780G$1,349
- Minimed 670G System$228
- TWIIST$186
- CeQur Simplicity$137
- ZEGALOGUE$132
- TOUJEO$115
How this compares
$221,549 in reported general payments places this provider in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 979 | $1,111,864 |
| JardianceEmpagliflozin | 651 | $550,229 |
| KerendiaFinerenone | 409 | $329,550 |
| FarxigaDapagliflozin Propanediol | 353 | $271,029 |
| MounjaroTirzepatide | 239 | $259,481 |
| Tresiba Flextouch U-100Insulin Degludec | 269 | $147,939 |
| TrulicityDulaglutide | 113 | $116,689 |
| RybelsusSemaglutide | 93 | $106,069 |
| Tresiba Flextouch U-200Insulin Degludec | 76 | $79,938 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 41 | $51,860 |
| Humalog Kwikpen U-100Insulin Lispro | 208 | $49,582 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 26 | $35,445 |
| Victoza 3-PakLiraglutide | 29 | $35,195 |
| Humulin R U-500Insulin Regular, Human | 23 | $33,404 |
| Novolog FlexpenInsulin Aspart | 168 | $33,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $138,406 | $1,220,8041,083 claims |
| Boehringer IngelheimJardiance | $56 | $550,229651 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $266 | $383,706391 claims |
| BayerKerendia | $27,299 | $329,550409 claims |
| AstraZenecaFarxiga | $43,223 | $271,029353 claims |
| AbbVieSynthroid | $32 | $4,19554 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Goldsboro
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- John BuseChapel Hill$460K
- Denis BeckerRaleigh$459K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.